TY - JOUR AU - Hamada, Tsuyoshi AU - Kosumi, Keisuke AU - Nakai, Yousuke AU - Koike, Kazuhiko PY - 2018 TI - Surrogate study endpoints in the era of cancer immunotherapy JF - Annals of Translational Medicine; Vol 6, Supplement 1 (November 29, 2018): Annals of Translational Medicine Y2 - 2018 KW - N2 - The choice of a primary endpoint is a matter of ongoing debate in the design of clinical oncology trials testing new treatment regimens. Overall survival (OS) time of patients serves as a gold-standard endpoint in phase III clinical trials testing first-line chemotherapy for cancers, because this outcome variable ultimately represents survival benefits from chemotherapy regimens and has minimal measurement errors. UR - https://atm.amegroups.org/article/view/21385